Swissmedic is reducing the fees for processing applications to non-commercially funded clinical trials by 80% effective 1 July 2024. In doing so, the Therapeutic Products Agency is making an important contribution to Switzerland as a research hub. The quality and method of assessment of submissions by Swissmedic remain unchanged.
01.07.2024
Swissmedic is complying with requests made by Parliament and the Federal Council, who are seeking to promote non-commercial research by lowering fees. Independent researchers are the intended beneficiaries – i.e. mainly university institutions, non-university hospitals and other primarily non-commercial research bodies. The fee reduction is being introduced on the basis of overriding public interest (Art. 12 FeeO-Swissmedic) (Article 12 of the Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products.). This interest was expressed in a number of procedural requests aimed at promoting university and independent research in Switzerland.
Researchers can apply to Swissmedic for a fee reduction using the relevant form.